Protein Expression of LOX-1, Enos and PPARγin Liver of Rats with Type 2 Diabetes and Intervention of Rosiglitazone

HU Li-ye,SONG Guang-yao,ZHU Lv-yun,WANG Chao,WANG Zhi-qiang
DOI: https://doi.org/10.3969/j.issn.1002-3429.2015.06.039
2015-01-01
Abstract:Objective To study the protein expression of LOX-1, eNOS and PPARγin livers in type 2 diabetes rats, and to study the intervention effect of rosiglitazone. Methods A total of 80 male Wistar rats were randomized to control group, high fat diet group, diabetes group, and Rosiglitazone treatment group. With 20 rats in each group. The rats in the control group were fed with normal diet, the other 3 groups were fed with high fat diet, type 2 diabetes models were developed in diabetes group and Rosiglitazone group. Rosiglitazone group was treated with Rosiglitazone. After treatment with Rosiglita-zone for 6 weeks and 12 weeks, the rats were sacrificed. Liver tissues were collected for protein expression of LOX-1, eNOS, PPARγ. Results ① Expression of LOX-1:Compared with control group and Rosiglitazone group, the liver protein expres-sion of LOX-1 in diabetes group was up-regulated 6 weeks after the model was established(P<0. 01). And compared with di-abetes group, the expression of LOX-1 in Rosiglitazone group was down-regulated 6 weeks after the model was established (P<0. 01). Compared with control group, the expressions of LOX-1 in high fat diet group, diabetes group and Rosiglitazone group were up-regulated 12 weeks after the model was established(P<0. 01). The expression of LOX-1 in diabetes group and Rosiglitazone group were up-regulated compared with those in high fat diet group 12 weeks after the model was established (P<0. 01). The expression of LOX-1 in Rosiglitazone group was down-regulated compared with those in diabetes group 12 weeks after the model was established(P<0. 01). ②Expression of eNOS:Compared with control group, the liver protein ex-pression of eNOS in high fat diet group, diabetes group and Rosiglitazone group were down-regulated 6 weeks and 12 weeks af-ter the model was established(P<0. 01). And compared with high fat diet group, the expressions of eNOS in diabetes group and Rosiglitazone group were down-regulated 6 weeks and 12 weeks after the model was established(P<0. 01). The expres-sion of eNOS in Rosiglitazone group was up-regulated compared with that of diabetes group 12 weeks after the model was estab-lished (P<0. 01). ③Expressions of PPARγ:6 weeks and 12 weeks after the model was established, compared with control group, the liver protein expressions of PPARγin high fat diet group, diabetes group and Rosiglitazone group were up-regulated (P<0. 01). And the expressions of PPARγ in diabetes group and Rosiglitazone group were up regulated more than that of high fat diet group(P<0. 01). The expression of PPARγin Rosiglitazone group was down-regulated more than that of diabetes group(P<0. 01). Conclusion Both hyperglycemia and hyperlipidemia can induce abnormal protein expression of LOX-1, eNOS and PPARγ in liver. When hyperglycemia coexists with hyperlipidemia, the abnormal expression is more obvious and thiazolidinediones Rosiglitazone drug has some reversing function in the abnormal expression.
What problem does this paper attempt to address?